Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 710 participants.

Also called NCT06822790

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 710 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06822790
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Croatia, Czechia, France, Germany, Hungary, Italy, Japan, Latvia, Lithuania, New Zealand, Poland, Romania, Slovakia, South Africa, Spain, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06822790. Allocation not applicable; no masking; primary purpose treatment. Start 2025-04-09 (actual); primary completion 2028-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
Acronym
SHASTA-10
Condition
Hypertriglyceridemia
Intervention (Drug)
Plozasiran Injection
Lead sponsor
Arrowhead Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct06822790
Content hash
6211ed7023b4b0c477726d36a8ec4b9bf8049a849e4b3e0ff3e9a9e2a6fd815e